别称： B-lymphocyte antigen CD19, Cluster of Differentiation 19, B-Lymphocyte Surface Antigen B4, T-Cell Surface Antigen Leu-12, CVID3 概述： 悉得（Syd Labs）提供重组小鼠 IgG1 同 ...

别称： B-lymphocyte antigen CD19, Cluster of Differentiation 19, B-Lymphocyte Surface Antigen B4, T-Cell Surface Antigen Leu-12, CVID3 概述： 悉得（Syd Labs）提供重组小鼠 IgG1 同 ...

CD19-CD22 CAR-T cells is under clinical development by Shanghai Biomed-Union Biotechnology and currently in Phase II for Unspecified B-Cell Lymphomas.

Selective depletion of B lymphocytes could represent a novel approach to the management of patients with newly diagnosed type 1 diabetes mellitus (T1DM), according to phase II data reported by the ...

More importantly, most patients treated with CD19 or B cell maturation antigen ... including tumor-infiltrated lymphocyte (TILs), CAR-T cells, and T cell receptor (TCR)-T cells, to overcome ...

The addition of Monjuvi to standard-of-care therapy reduced the risk of disease progression, relapse, or death in patients ...

Tumor-infiltrating lymphocytes (TILs ... and often restricted access to these therapies. Anti-CD19 CAR-T cells can expand rapidly in the recipient, causing significant increases in proinflammatory ...

It is a two-component therapy consisting of SYNCAR-001, an autologous CD19-targeting chimeric antigen receptor T (CAR-T) cell which expresses an engineered IL-2 receptor, and STK-009, an ...